Status:
COMPLETED
Exploring Buckwheat's Glucose Lowering Potential
Lead Sponsor:
St. Boniface Hospital
Collaborating Sponsors:
University of Manitoba
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-70 years
Brief Summary
Bioactive components in buckwheat enhance insulin sensitivity in Type 2 diabetes by improving glucose uptake and utilization through a unique mechanism that operates independent of insulin.
Detailed Description
This is a single site, double-blind, randomized, controlled study designed to explore buckwheat's glucose lowering effects in healthy volunteers and volunteers with type 2 diabetes. A total of 24 volu...
Eligibility Criteria
Inclusion
- aged 18 to 70 years
- normal glycated hemoglobin (\<6% healthy, \<7.5% diabetic)
- absence of chronic conditions (except Type 2 diabetes)
- must be able to read and sign consent
- must be able to comply with protocol requirements
Exclusion
- allergies to eggs, buckwheat, rice flour, or sugar substitutes (Splenda)
- acute or chronic conditions (except Type 2 diabetes)
- blood glucose \>10mmol/L at beginning of test session
- medications that affect glycemic control
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00841503
Start Date
September 1 2008
End Date
March 1 2012
Last Update
March 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
I.H. Asper Clinical Research Institute
Winnipeg, Manitoba, Canada, R2H 2A6